Oncology Nursing News

Abbey Kaler, MS, APRN, FNP-C, CMSRN, demonstrated extraordinary oncology nursing by being a consistent champion of the patient’s voice.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

The approval of the Udenyca autoinjector offers easy-to-use design for delivery of the biosimilar pegfilgrastim-cbqv.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Thank you for reading Oncology Nursing News® in 2022. We look forward to bringing you more news in 2023.

In November 2022, HER2-directed therapies made headlines in breast cancer as did innovations to help individuals who are often overlooked in oncology care.

Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.

The ideal model for promoting effective shared decision-making involves tailored caregiver education, adequate time before treatment, and use of multidisciplinary support.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from June 2022.

This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of medical cannabis, and more.

This year’s conference highlighted advances in natural killer cells, CD39 and KRAS G12C inhibitors, and CAR T-cell therapies.

Laura Zitella, MS, RN, ACNP-BC, AOCN, reviews a case study where a 52-year-old female patient with metastatic colorectal carcinoma begins experiencing diffuse abdominal pain.

The FDA has approved selinexor as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma, not otherwise specified, who have received ≥2 prior therapies.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE Activity Worth 1.0 Contact Hour Featuring Highlights From the Year's Largest Oncology Conference and Peer Perspectives From Oncology Nurses.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE lesson worth 1.0 contact hour that is focused on supportive care and research from the 2013 Genitourinary and Gastrointestinal Cancers Symposia.

CE lesson worth 1.0 contact hour that is focused on research from the 2012 American Society of Hematology Annual Meeting and the San Antonio Breast Cancer Symposium.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.

CE lesson worth 1.0 contact hour that is intended for advanced practice nurses, registered nurses, and other healthcare professionals who care for cancer patients.